Since CYP3A4 inhibitors usually inhibit P‐gp, characterizing the extent to which rimegepant interactions are attributable to CYP3A4 inhibition from those due to transporter inhibition will further facilitate the safe and appropriate use of rimegepant in individuals with migraine. Here, CYP3A4 is linked to migraine disorder.